MARKET

CRIS

CRIS

Curis
NASDAQ
1.030
+0.119
+13.11%
After Hours: 1.030 0 0.00% 18:03 02/06 EST
OPEN
0.9400
PREV CLOSE
0.9106
HIGH
1.050
LOW
0.9201
VOLUME
521.64K
TURNOVER
--
52 WEEK HIGH
3.570
52 WEEK LOW
0.7710
MARKET CAP
13.32M
P/E (TTM)
-0.2802
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRIS last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at CRIS last week (0119-0123)?
Weekly Report · 01/26 09:54
Weekly Report: what happened at CRIS last week (0112-0116)?
Weekly Report · 01/19 09:58
Curis Targets BTKi-Exposed CLL With New Emavusertib Combo Trial: What Investors Should Watch
TipRanks · 01/15 16:32
CURASIGHT ANNOUNCES ENCOURAGING PRELIMINARY DATA FROM PHASE 1 TRIAL EVALUATING FIRST-IN-CLASS RADIOPHARMACEUTICAL UTREAT IN HIGH-GRADE GLIOMAS®
Reuters · 01/12 18:03
Weekly Report: what happened at CRIS last week (0105-0109)?
Weekly Report · 01/12 09:56
CURIS ANNOUNCES CLOSING OF PRIVATE PLACEMENT TOTALING UP TO $80.8 MILLION IN GROSS PROCEEDS
Reuters · 01/09 13:00
Curis Announces PIPE Financing and Strategic Capital Strengthening
TipRanks · 01/08 11:31
More
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.